TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
-0.55%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$1.51B
AUM Growth
+$1.51B
(+8%)
Cap. Flow
+$174M
Cap. Flow
% of AUM
11.53%
Top 10 Holdings %
Top 10 Hldgs %
37.54%
Holding
194
New
40
Increased
62
Reduced
19
Closed
11
Top Buys
| 1 |
Galapagos
GLPG
|
$40.2M |
| 2 |
Relay Therapeutics
RLAY
|
$18.5M |
| 3 |
Replimune Group
REPL
|
$18.2M |
| 4 |
Legend Biotech
LEGN
|
$14.6M |
| 5 |
Immunocore
IMCR
|
$13.3M |
Top Sells
| 1 |
ITOS
iTeos Therapeutics
ITOS
|
$16.8M |
| 2 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$13M |
| 3 |
Immunome
IMNM
|
$10.5M |
| 4 |
ANI Pharmaceuticals
ANIP
|
$7.32M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$6.4M |
Sector Composition
| 1 | Healthcare | 94.65% |
| 2 | Technology | 1.65% |
| 3 | Communication Services | 1.35% |
| 4 | Consumer Discretionary | 0.56% |
| 5 | Financials | 0.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Edgewise Therapeutics
EWTX
$1.54B
| $8.01M | 0.53% |
+300,000
| New | +$8.01M |
|
52
Adicet Bio
ACET
$60.8M
| $7.84M | 0.52% |
8,145,988
-70,972
| -0.9% | -$68.3K |
|
53
ESSA Pharma
EPIX
$11.2M
| $7.7M | 0.51% |
+4,300,000
| New | +$7.7M |
|
|
BIOA
54
BioAge Labs, Inc. Common Stock
BIOA
$170M
| $7.63M | 0.51% |
+1,318,361
| New | +$7.63M |
|
55
AbCellera Biologics
ABCL
$1.19B
| $7.57M | 0.5% |
2,582,816
+282,816
| +12% | +$829K |
|
56
CytomX Therapeutics
CTMX
$350M
| $7.53M | 0.5% |
7,311,760
-500,000
| -6% | -$515K |
|
|
OMIC
57
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $7.23M | 0.48% |
372,000
| – | – |
|
58
ImmunityBio
IBRX
$2.24B
| $7.2M | 0.48% |
+2,814,192
| New | +$7.2M |
|
59
Insmed
INSM
$30.3B
| $6.9M | 0.46% |
100,000
| – | – |
|
|
ONC
60
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.5B
| $6.83M | 0.45% |
37,000
| – | – |
|
61
Ventyx Biosciences
VTYX
$184M
| $6.79M | 0.45% |
3,100,000
| – | – |
|
62
Journey Medical
DERM
$187M
| $6.75M | 0.45% |
+1,725,569
| New | +$6.75M |
|
63
BioCryst Pharmaceuticals
BCRX
$1.74B
| $6.02M | 0.4% |
800,000
| – | – |
|
64
Dianthus Therapeutics
DNTH
$781M
| $5.77M | 0.38% |
264,692
| – | – |
|
65
Nkarta
NKTX
$149M
| $5.71M | 0.38% |
2,293,719
+1,643,719
| +253% | +$4.09M |
|
66
ALX Oncology
ALXO
$54.6M
| $5.51M | 0.36% |
3,296,883
-907,852
| -22% | -$1.52M |
|
67
Biogen
BIIB
$20.5B
| $5.35M | 0.35% |
35,000
| – | – |
|
68
Ionis Pharmaceuticals
IONS
$9.64B
| $5.24M | 0.35% |
150,000
| – | – |
|
69
Biohaven
BHVN
$1.71B
| $5.23M | 0.35% |
140,000
| – | – |
|
70
Seer Inc
SEER
$114M
| $5.07M | 0.34% |
2,194,423
-105,577
| -5% | -$244K |
|
71
Coherus Oncology, Inc. Common Stock
CHRS
$146M
| $5.04M | 0.33% |
3,650,000
+1,300,000
| +55% | +$1.79M |
|
72
Kezar Life Sciences
KZR
$28.5M
| $4.84M | 0.32% |
720,000
+355,970
| +98% | +$2.39M |
|
73
Novavax
NVAX
$1.2B
| $4.82M | 0.32% |
600,000
-400,000
| -40% | -$3.22M |
|
|
ALMS
74
Alumis Inc. Common Stock
ALMS
$483M
| $4.72M | 0.31% |
600,000
+173,406
| +41% | +$1.36M |
|
75
Cytokinetics
CYTK
$5.98B
| $4.7M | 0.31% |
100,000
| – | – |
|